Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,810,000 shares, a growth of 145.8% from the January 15th total of 736,500 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 9.4% of the company’s shares are short sold.

Vigil Neuroscience Trading Up 0.6 %

Vigil Neuroscience stock traded up $0.02 during mid-day trading on Wednesday, hitting $2.67. The stock had a trading volume of 961,942 shares, compared to its average volume of 1,990,923. The firm has a market capitalization of $108.95 million, a P/E ratio of -1.29 and a beta of 1.84. The firm’s 50 day moving average is $2.03 and its 200 day moving average is $2.95. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06.

Institutional Trading of Vigil Neuroscience

Several hedge funds have recently bought and sold shares of VIGL. Blair William & Co. IL purchased a new stake in Vigil Neuroscience in the 4th quarter worth $551,000. abrdn plc raised its position in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience during the 3rd quarter valued at about $442,000. Point72 Asset Management L.P. raised its position in shares of Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after buying an additional 115,000 shares in the last quarter. Finally, Walleye Capital LLC raised its position in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after buying an additional 92,217 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Thursday, January 23rd. Wedbush raised their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. William Blair started coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating for the company. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience currently has an average rating of “Buy” and an average target price of $19.75.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.